Treatments > Stem Cell Transplants
Last update: 05/09/2008 |
INTRO
| MENU
TOPIC SEARCH:
ASCO.org
| JCO.org
| Medscape
| ClinicalTrials.gov
| Oncolink
Stem cell transplants
(bone marrow transplant) - the goal of this treatment is to cure the
patient with aggressive therapies that partially or completely kill
off (ablate) the normal stem cells in the marrow. These cells are then replaced with the patient's own stem cells
- harvested prior to treatment, or obtained from a donor.
Bone marrow is the spongy tissue found in the cavities of the body's bones, where all the body's blood cells are produced.
Stem cells are
immature cells found in the marrow and peripheral blood that develop
or mature into red blood cells, white blood cells and platelets.
Types:
allogeneic and autologous are the two main types of
stem cell transplantation (or rescue). Allogeneic stem cells
are derived from a matched donor (such as a sibling); in the
autologous type, stem cells are derived from the patient.
Each type has unique risks and benefits, and which is preferred
can depend on the clinical details. See for example, one
study comparing SCT types
General exclusion
criteria? "Stem cell transplant (SCT)
protocols often require complete response with initial therapy as
a requirement for entry, although "good partial
remission" may be acceptable at certain centers. *
Other limitations for SCT protocols
include age greater than 60 or 65 years, significant chronic
obstructive pulmonary, renal, or cardiac disease, a poor
performance status, and central nervous system involvement."
*
* Source: Treatment of relapsed
aggressive lymphomas: regimens with and without high-dose therapy
and stem cell rescue.
National Bone Marrow Donor
Program
call 800 MARROW2 ( 800 627-7692 )
and become a registered donor
BMTInfoNet
(Stem Cell Transplant Support)
2900 Skokie Valley Road, Suite B
Highland Park, IL 60035
Search
for Stem Cell Transplant Centers BMTinfoNet
Also
provides: background, the number of transplants done,
Minimum Donor Match Criteria, Contacts, Support Groups Available
Phone: 847-433-3313 - during regular business hours, toll-free
888.597.7674
Background:
Also see Stem Cell Transplants: When and Which
Type?
 |
About Hematopoietic Stem Cell Transplantation e-medicine
|
|
|
|
Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation:
Questions and Answers cis.nci.nih.gov
|
|
Comparison of
autologous and allogeneic hematopoietic stem cell transplantation
for follicular lymphoma - Blood First Edition Paper July 31,
2003 Summary
|
| Eligibility Criteria
for Stem Cell transplants cancer.dartmouth.edu
|
| Long-term results favor allogeneic over autologous
hematopoietic stem cell transplantation in patients with
refractory or recurrent indolent non-Hodgkin's lymphoma.
Ann Oncol. 2003 May;14(5):737-44. PMID:
12702528 | Related
articles
|
|
Managing Indolent Lymphomas in Relapse asheducation.org
Working Our Way Through a Plethora of Options (includes SCT
guidance)
|
|
SCT for Low grade
Lymphoma asheducationbook.org
/2004 full text | PAL's
readable version
"In Section III, Dr. Koen Van Besien provides
a well-documented update on outcomes associated with
autologous and allogeneic stem cell transplantation for
FL. The results of trials of autologous stem cell
transplantation in first remission and recent data supporting
a role for graft purging are discussed.
Based on the
premise that a graft-versus-lymphoma effect is operative in
FL, reduced-intensity allogeneic transplantation is the preferred
approach in many cases, and recently reported results are
summarized. Criteria for patient selection and the
optimal role of transplantation in the overall
therapeutic plan for the patient with FL are presented."
|
| Stem Cell Transplants - Guest Author Series PLWC.org
(2007)
1) Understanding Bone Marrow and Stem Cell Transplantation
Part
I
2) Bone Marrow and Stem Cell Transplantation: Special types of
transplantation Part
II
3) Side Effects of Bone Marrow and Stem Cell Transplantation
Part
III
4) Questions and Answers About Bone Marrow and Stem Cell
Transplantation Part
IV
|
| Understanding bone marrow and stem cell transplantation,
Part I PLWC.org
"Blood and marrow transplantation is a medical (not a
surgical) procedure, lasting weeks to months from start to finish,
in which diseased marrow (a spongy, fatty tissue found on the
inside of larger bones) or immune system is replaced by a
healthier one. For people with cancer, the goal is to destroy
every last cancer cell. For people with genetic diseases, the goal
is correction of the underlying genetic disease."
|
|
|
|
Lymphoma subtype-specific
|
|
|
| Mantle Cell
The Role of Autologous Transplantation in the Management of Mantle Cell Lymphoma:
A Study From the EBMT E. Vandenberghe, C. Ruiz de Elvira, P. Isaacson, E. Lopez-Guillermo,
E.
Conde, C. Gisselbrecht, F. Guilhot, A. Goldstone, N. Schmitz PDF
| PDF-Help
|
Resources
| BMTInfoNet (Stem Cell Transplant Support)
2900 Skokie Valley Road, Suite B
Highland Park, IL 60035
Recommended site: Search
for Stem cell Transplant Centers BMTinfoNet
Also
provides: background, Number of transplants done,
Minimum Donor Match Criteria, Contacts, Support Groups Available
Phone: 847.433.3313 - during regular business hours, toll-free
888.597.7674
|
|
|
| BMT Worksheet - Factors to consider when
choosing a center fhcrc.org
- PDF
|
|
|
| What to bring to hospital cyberfamily
|
| How long does it take to have an SCT? AM's story
|
| Guidelines
for preventing infection PDF
| PDF-Help
|
|
|
|
Research News |
|
RIT and SCT:
Tositumomab (Bexxar) Plus Stem Cell Transplant Induces Remission
in Refractory B-Cell Lymphoma Medscape
free login req.
This "interesting approach"
increases the possibility of reduction of tumor burden before
transplant, Dr. Schrier said. "This looks really
promising."
|
|
Treatment related
mortality: Cytochrome P450 2C19 loss-of-function polymorphism is
associated with an increased treatment-related mortality in patients
undergoing allogeneic transplantation. Bone Marrow Transplant. 2007
Oct;40(7):659-64. Epub 2007 Aug 6. PMID:
17680025
Comment: Probably this finding needs to be validated (reproduced by
an independent group) before being declared as true, but it shows how
normal variations in patients (a polymorphism) can affect
outcomes. In this case, treatment-related mortality is strongly
correlated with a specific normal genetic variation
|
|
Side effects:
Cognitive function recovers after stem cell transplant oncolink.org
To investigate, the researchers initially studied 286 patients who
were randomized to be tested pre-transplant and 6 and 12 months, and
another 124 were tested at 6 and 12 months. Eighty-three patients who
were tested at 12 months only were not included in the analysis.
|
|
The impact of histologic grade on the outcome
of high-dose therapy and autologous stem cell transplantation for
follicular lymphoma nature.com
|
|
Antibiotic prophylaxis in neutropenic patients:
new evidence, practical decisions.
Cancer. 2006 Oct 15;107(8):1743-51. Review. PMID:
16977651
New evidence shows that antibiotic prophylaxis in neutropenic
patients reduces mortality, febrile episodes, and bacterial
infections.
|
|
Prognostic value of FDG-PET scan imaging in
lymphoma patients undergoing autologous stem cell transplantation.
Bone Marrow Transplant. 2006 Jun 12; PMID: 16770314
A positive FDG-PET scan after salvage chemotherapy and prior
ASCT indicates an extremely poor chance of durable response after
ASCT.
|
|
Comorbidity Index Aids Stem Cell Transplant Choices
Medscape
(free login req.)
"reporting comorbidity data of the type used in this index
will likely become as important as defining cancer diagnosis,
disease stage, remission status, and other more familiar
prognostic variables."
|
|
High-dose radioimmunotherapy (Bexxar) versus conventional
high-dose therapy and autologous hematopoietic stem cell
transplantation for relapsed follicular non-Hodgkin's lymphoma: a
multivariable cohort analysis. Blood. 2003 May 15 PMID: 12750161 PubMed
|
| The Role of Radiolabeled Monoclonal Antibodies as Part of the Conditioning Regimen for Non-Hodgkin’s Lymphoma Autografts John W. Sweetenham
~ University of Colorado Health Sciences Center, Denver, Colorado, USA
static.cjp.com
PDF
|
| Long-term survival of patients with resistant
lymphoma treated with tandem stem cell transplant.
Leuk Lymphoma. 2005 Mar;46(3):405-14. PMID:
15621831 | Related
articles
|
| Stem cell transplantation in follicular lymphoma:
progress at last?
Bone Marrow Transplant. 2004 Oct 18 PMID:
15489883 | Related
articles
|
| Myeloablative radiochemotherapy followed by autologous stem
cell transplantation in first remission prolongs progression-free
survival [Compared to consolidation with INF] in follicular
lymphoma: results of a prospective, randomized trial of the German
Low-Grade Lymphoma Study Group bloodjournal.org
Oct 2004 Commentary
|
| Infused CD34 cell dose, but not tumour cell content
of peripheral blood progenitor cell grafts, predicts clinical outcome in
patients with diffuse large B-cell lymphoma and follicular lymphoma
grade 3 treated with high-dose therapy. Br J Haematol. 2004
Jun;125(5):605-12. PMID:
15147376 Also see Lazarus.pdf
|
| Palifermin (rHu-KGF) Improves Quality of Life in Patients Undergoing Stem Cell Transplantation
CancerConsultants
2003
|
| ASCO Comments on FDA Proposal to Regulate Stem
Cell Products, April 17, 1997 the FDA
Proposal -PDF
|
| Search Lymphoma
abstracts from the Official Journal of the American Society
for
Blood and Marrow Transplantation
|
|
|
|
-
Life After SCT |
| Study Finds Overall Health and Quality of Life Intact
10 Years
After Stem-Cell Transplantation prnewswire.com
|
|
Patient Stories
Cyberfamily
| Preparations for
homecoming Cyberfamily
|
|
Life after High Dose Treatment and Stem Cell Support CancerBacup
|
|
Guidelines
for preventing infection PDF
| PDF-Help
|
|
Adjuvants
|
Adjuvants
are practices or agents that may improve how a therapy works, or that
may reduce side effects without compromising efficacy.
|
ASH 2002:
Proleukin®
Plus Rituxan® may Reduce Recurrences Following Stem Cell Transplant
in Non-Hodgkin’s Lymphoma CancerConsultants.com
|
| Cytokine improves immune function after bone marrow
transplantation in mice www.oncolink.com
|
|
FILGRASTIM: Treatment of aggressive non-Hodgkin's
lymphoma with chemotherapy in combination with filgrastim. Drugs.
2002;62 Suppl 1:33-46. Review. PMID: 12479593 PubMed
|
|
Parenteral
glutamine protects hepatic function during bone marrow transplantation.
Brown SA
et.al.
|
|
Glutamine
supplementation in cancer patients receiving bone marrow transplantation
and high dose chemotherapy. J Nutr. 2001 Sep;131(9 Suppl):2578S-84S;
discussion 2590S. Review. PMID: 11533316
|
|
Oral
and parenteral glutamine in bone marrow transplantation: a randomized,
double-blind study. Schloerb PR, Skikne BS. PubMed
|
|
Patient
Stories |
|
|
